Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5776133 | 0.92 | HTT (0.39) | HTTGAAUSP2KMT2AKDM4E | |
| SCHEMBL5774126 | 0.80 | MEN1 (0.43) | HTTUSP2KMT2APOLBMEN1 | |
| SCHEMBL5777123 | 0.78 | HPGD (0.50) | GAAUSP2KMT2APOLBMEN1 | |
| SCHEMBL5772881 | 0.76 | HDAC8 (0.32) | KMT2AKDM4EMEN1 | |
| Trifluoroacetic Acid SCHEMBL5771830 | 0.76 | DRD2 (0.54) | HTT | |
| SCHEMBL5774834 | 0.76 | MAPT (0.45) | HTTUSP2KMT2AMEN1MAPT | |
| Trifluoroacetic Acid SCHEMBL5777437 | 0.75 | ACKR3 (0.41) | HTTUSP2MAPT | |
| Trifluoroacetic Acid SCHEMBL5771064 | 0.74 | LMNA (0.44) | KMT2AL3MBTL1MEN1MAPT | |
| SCHEMBL5769962 | 0.74 | SMN1; SMN2 (0.41) | KMT2AKDM4EMEN1MAPTCYP2C9 | |
| SCHEMBL5773998 | 0.73 | FFAR1 (0.46) | USP2KDM4EL3MBTL1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | HTT 4375/4885GAA 2207/4885USP2 3981/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | HTT 3773/4885GAA 1930/4885USP2 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.